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Abstract
We used differential scanning calorimetry (DSC) and electron spin resonance (ESR) spectroscopy to investigate the
interactions of Losartan, a potent, orally active Angiotensin II AT1 receptor antagonist with phospholipid membranes. DSC
results showed that Losartan sensitively affected the chain-melting behavior of dimyristoylphosphatidylcholine (DMPC) and
dipalmitoylphosphatidylcholine (DPPC) bilayer membranes. ESR spectroscopy showed that phosphatidylcholines spin-
labeled at the 5-position of the sn-2 acyl chain (n-PCSL with n = 5), incorporated either in DMPC or DPPC bilayers
containing Losartan, were restricted in motion both in the gel and in the liquid^crystalline membrane phases, indicating a
location of the antagonist close to the interfacial region of the phosphatidylcholine bilayer. At high drug concentrations
(mole fractionv x = 0.60), the decrease in chain mobility registered by 5-PCSL in fluid-phase membranes is smaller than that
found at lower concentrations, whereas that registered by 14-PCSL is further increased. This indicates a different mode of
interaction with Losartan at high concentrations, possibly arising from a location deeper within the bilayer. Additionally,
Losartan reduced the spin^spin broadening of 12-PCSL spin labels in the gel-phase of DMPC and DPPC bilayers. As a
conclusion, our study has shown that Losartan interacts with phospholipid membranes by affecting both their thermotropic
behavior and molecular mobility. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiotensin II (ANG II) is an endogenous octa-
peptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) produced
by the renin^angiotensin system. This hormone is the
body’s most potent vasoconstrictor. It a¡ects the
blood pressure directly by constriction of the blood
vessels and, indirectly, by inducing the release of al-
dosterone from the cortex of the adrenal gland.
Besides its action as a vasoconstrictor, ANG II is
involved in many biological e¡ects and it has a wide
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range of target tissues [1]. It induces the release of
catecholamines in the adrenal medulla and the syn-
thesis of prostaglandins in the kidney. Additionally,
it stimulates ovulation, and glycogenolysis in the liv-
er. In the brain, ANG II induces the release of vaso-
pressin and the release of the corticotropin hormone
(ACTH) in the hypophysis.
ANG II exerts its biological function by interact-
ing with speci¢c cellular receptors found in the mem-
branes of many tissues. This interaction activates a
messenger system which ¢nally leads to the biological
response [2]. Two major subtypes of receptors, des-
ignated as AT1 and AT2, have been identi¢ed in a
variety of animal and human tissues [3,4].
The major physiological functions of ANG II have
hitherto been attributed to the G-protein-coupled
AT1 receptor [5]. Therefore, antagonism of ANG II
at its receptor by biologically active molecules would
be the most selective method for the treatment of
hypertension [6]. Since the discovery of non-peptide
ANG II receptor antagonists in 1982 by Takeda [7],
a large number of such antagonists has been synthe-
sized [8^10].
Losartan (Fig. 1) is a potent and selective orally
active non-peptide receptor antagonist, developed
jointly by the Du Pont (DUP 753) and Merck
(MK 954) companies and later distributed solely by
MSD (COZAAR or LORZAAR), which recently re-
ceived FDA approval as a new drug [11,12].
Existing evidence suggests that ANG II also inter-
acts with membranes. Radioimmunoassays and re-
ceptor-binding assays revealed the interference of
ANG II interactions by some lipids [13,14]. It is
also known that ANG II is able to mediate the trans-
port of Mn2 across phosphatidylcholine bilayers
[15]. Binding interactions between human ANG II
and dipalmitoylphosphatidylcholine (DPPC) vesicles
have been detected by measuring the selective proton
spin-lattice relaxation rates of aromatic protons
within the peptide [16]. Recently, by using a combi-
nation of 31P-NMR spectroscopy and di¡erential
scanning calorimetry (DSC), we showed that ANG
II a¡ects the phase properties of DPPC bilayers and
produces e¡ects on the phospholipid head groups
[17]. However, the interactions of non-peptide AT1
receptor antagonists with membranes have not been
studied in detail. In the present work, we used high
resolution DSC and electron spin resonance (ESR)
spectroscopy to investigate the interaction of Losar-
tan, the AT1 receptor antagonist, with phosphatidyl-
choline bilayers. Phosphatidylcholine is the most im-
portant structural class of mammalian membrane
phospholipid.
DSC is a thermodynamic technique which allows
us to investigate the thermotropic properties of mem-
branes in the absence and presence of biologically
active molecules [18^21]. Spin label ESR spectros-
copy has been used extensively in studies of lipid
chain dynamics and of the molecular location of pro-
teins in phospholipid bilayers [22^25].
2. Materials and methods
2.1. Materials
Dimyristoylphosphatidylcholine (DMPC) and di-
palmitoyl-phosphatidylcholine (DPPC) were ob-
tained from Avanti Polar Lipids (Birmingham, Ala-
bama, USA). Losartan was kindly provided by
Merck’s Research Laboratories (MSD Sharp and
Dohme, Haar, Germany). Phospholipid spin labels
(n-PCSL) were synthesized by B. Angerstein as de-
scribed in [26].
2.2. Di¡erential scanning calorimetry
Thermograms of hydrated mixtures of phospho-
lipids with Losartan at molar ratios of 99:1
(x = 0.01), 95:5 (x = 0.05), 90:10 (x = 0.10), 80:20
(x = 0.20), 60:40 (x = 0.40) and 50:50 (x = 0.50)
of lipid:drug were obtained.
The preparation of DSC samples was identical for
the two phospholipids used in this study. A 7-mgFig. 1. Chemical structure of Losartan potassium salt.
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amount of the phospholipid and appropriate
amounts of Losartan were codissolved in a dichloro-
methane/methanol mixture (2:1, v/v). The organic
solvent was evaporated under a stream of oxygen-
free N2, at a temperature above the corresponding
phase transition temperature of the phospholipid.
The lipid/drug mixtures were then dried under high
vacuum overnight.
DSC was performed with a Model 4207 heat-£ow
calorimeter from Hart Scienti¢c (Pleasant Grove,
Utah). The dried samples were hydrated with 200 Wl
double distilled and deionized water and transferred
to the DSC ampoules. Distilled and deionized water
was used as a reference sample. Prior to scanning,
the samples were held above their phase transition
temperature for 10 min to ensure complete hydra-
tion. All samples were scanned at least twice until
identical thermograms were obtained using a scan
rate of 10‡C/h. Integration of the calorimetric endo-
therms was performed using the software supplied
with the instrument.
2.3. Electron spin resonance spectroscopy
Dried mixtures of phospholipids and Losartan
were prepared following the procedure described
above. In the case of samples for ESR spectroscopy,
1 mg of the phospholipid and appropriate amounts
of the antagonist were used and 1 mol% of the spin-
labeled lipid in dichloromethane was added.
After hydration with 50 Wl distilled and deionized
water, the samples were transferred to ESR capilla-
ries of 1 mm diameter and concentrated by centrifu-
gation (10 000 rpm, for 30 min at 4‡C). ESR spectra
were obtained on a Varian E-12 Century Line 9 GHz
spectrometer. ESR capillaries were inserted in a
standard 4-mm quartz ESR tube containing light
silicone oil for thermal stability. A pure nitrogen
gas-£ow system was used to regulate the tempera-
ture. ESR spectra were recorded using a modulation
frequency of 100 kHz, modulation amplitude of
1.25 G peak-to-peak and total scan width 100 G.
Outer hyper¢ne splittings (2Amax) were used to
characterize the rotational disorder and rotational
rates of the spin-labeled lipid chain segments [27].
This quantity is de¢ned on the experimental spectra
given subsequently (Fig. 4). In general, the values of
2Amax will depend both on the order parameter of
the spin-labeled chain segment and on rotational cor-
relation time. For £uid-phase membranes, it will de-
pend most strongly on the chain order, but in gel-
phase membranes, it will also depend strongly on the
(slow) rotational rates. For rotational mobility with
components in the slow-motional regime [28], the
change in this parameter, vAmax, therefore provides
a useful measure of the change in lipid chain mobility
induced by Losartan. Rapid isotropic rotation re-
duces Amax to A0 = 15.0 G, which is the isotropic
average hyper¢ne coupling constant [25]. Therefore,
vAmax/(Amax3A0) is the appropriate normalized
quantity that characterizes the changes in Amax.
3. Results
3.1. Di¡erential scanning calorimetry
The DSC traces of DMPC preparations containing
increasing concentrations of Losartan are shown in
Fig. 2. DSC thermograms of hydrated DMPC bilayers contain-
ing Losartan at the di¡erent mole fractions, x, indicated.
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Fig. 2. The hydrated pure DMPC shows a pretransi-
tion centered at 14.7‡C and a main phase transition
from the gel to the liquid crystalline phase at 23.8‡C,
in agreement with previous reports [29]. The pretran-
sition of DMPC is strongly a¡ected by the presence
of the antagonist in the membranes, being broad-
ened, shifted to much lower temperatures and al-
ready abolished at low concentration x = 0.05. At
Losartan concentrations up to x = 0.10, a progressive
shift of the main transition to lower temperatures
and a broadening of the half width of the corre-
sponding peak are observed, as is shown in Table
1. At mole fraction x = 0.10, a high temperature
shoulder is formed at around 23‡C. As the concen-
tration is increased to x = 0.50, this shoulder becomes
a new peak which is shifted to higher temperatures,
while the peak on the low temperature side is shifted
to lower temperatures. A broader intermediate peak
also appears close to the mid-point of the transition
region. Increase in the concentration of Losartan
therefore causes a large broadening in extent of the
transition region (ca. 20‡C at x = 0.5). Concomi-
tantly, the sample becomes highly viscous in the tran-
sition region. As shown in Table 1, the presence of
the drug does not a¡ect drastically the total enthalpy
change (vH) of the observed phase transition.
The DSC thermograms of hydrated pure DPPC
and mixtures with Losartan are shown in Fig. 3.
DPPC bilayers show a pretransition at 34.9‡C and
a main phase transition from the gel to the liquid
crystalline phase at 41.2‡C, in agreement with pre-
vious reports [29]. The incorporation of increasing
concentrations of Losartan results in a progressive
shift of the main transition to lower temperatures
and a broadening of the corresponding peak (Table
2). The pretransition is again strongly a¡ected and is
abolished at low concentration of the antagonist
(x = 0.10). The enthalpy change of the gel to liquid
crystalline phase transition of DPPC was not de-
creased very signi¢cantly by the incorporation of
Losartan (Table 2).
Table 1
Calorimetric peak temperatures (Tc), half-widths (vTc1=2) and total enthalpy changes (vH) of DMPC bilayers containing di¡erent con-
centrations of Losartan
Sample Tc (‡C)a vH (kcal/mol)a vTc1=2 (‡C)a
DMPC 14.7 23.8 1.0 5.3 1.2 0.3
+Losartan (x = 0.01) 10.0 23.5 0.4 5.2 2.6 0.5
+Losartan (x = 0.05) ^ 22.9 ^ 5.0 ^ 0.6
+Losartan (x = 0.10) ^ 22.1/23.2b ^ 4.8 ^ 0.5
+Losartan (x = 0.20) ^ 20.0/23.7 ^ 5.5 ^ 0.8/2.6b
+Losartan (x = 0.40) ^ 16.3/26.2 ^ 5.7 ^ 1.0/2.2
+Losartan (x = 0.50) ^ 14.3/29.0 ^ 6.7 ^ 1.8/3.1
aValues to the left of each column correspond to the pretransition and those to the right to the main phase transition.
bDouble values refer to the two outer peaks in the total endotherm.
Fig. 3. DSC thermograms of hydrated DPPC bilayers contain-
ing Losartan at the di¡erent mole fractions, x, indicated.
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3.2. Electron spin resonance spectroscopy
ESR spectra of phosphatidylcholines spin-labeled
at the 5-, 12- or 14-position of the sn-2 chain (5-
PCSL, 12-PCSL and 14-PCSL, respectively) incorpo-
rated into DMPC bilayers are compared in Fig. 4
(dotted lines) with the corresponding ones from prep-
arations containing Losartan at x = 0.10 (solid lines).
The spectra were obtained at di¡erent temperatures
in order to cover all mesomorphic phases of the bi-
layer membranes.
In the case of 5-PCSL spin labels, DMPC bilayers
exhibit a chain-melting phase transition in the
region around 23‡C, as is observed from the decrease
of the outer hyper¢ne splitting 2Amax (vAmax/
(Amax3A0) = 28.5% between 20 and 25‡C). The bi-
layers containing Losartan exhibit this transition in
a region somewhat below 23‡C. Additionally, in the
preparation containing Losartan, the spin labels are
more restricted in their motion in both the gel and
liquid^crystalline phases because the outer hyper¢ne
splitting 2Amax is increased in the presence of Losar-
tan, relative to the spectra in its absence (vAmax/
(Amax3A0) = 2.9% and 4.5% at 10‡C and 35‡C, re-
spectively). As is evident in Fig. 4, the spin^spin
broadening of 12-PCSL spin labels in the gel phase
of DMPC bilayers is reduced by the presence of Los-
artan in the membranes. Spin^spin broadening arises
from partial exclusion of the spin-labeled phospho-
lipids from the tightly packed DMPC molecules in
the gel phase. The reduction of spin^spin broadening
that is observed demonstrates that Losartan im-
proves the solubility of the lipid probes in the gel
phase. ESR spectra of 14-PCSL spin labels show
that the preparation containing the antagonist under-
goes a chain-melting phase transition in the region
around 20‡C while the corresponding pure lipid
preparation undergoes this transition in the region
around 23‡C. Moreover, in the presence of Losartan,
14-PCSL spin labels are more restricted in motion in
the gel phase, relative to in its absence (vAmax/
(Amax3A0) = 9.8% at 10‡C).
The concentration of the antagonist in DMPC bi-
layers was increased further to mole fractions
x = 0.40 and x = 0.60 and the corresponding ESR
spectra of 5- and 14-PCSL spin labels are shown in
Fig. 5. At mole fraction x = 0.40 (Fig. 5A), the e¡ects
of Losartan are qualitatively similar to those de-
scribed above for the lower mole fraction x = 0.10.
Quantitatively, the e¡ects are correspondingly larger.
The 5-PCSL spin labels are restricted in motion both
in the gel and in the liquid^crystalline phase, showing
greater increases in outer hyper¢ne splitting 2Amax
than at the lower Losartan concentration of
x = 0.10 (vAmax/(Amax3A0) = 3.0% and 8.3% at 10‡C
and 35‡C, respectively). Furthermore, the observed
chain-melting transition is shifted to lower temper-
atures than at mole fraction x = 0.10. ESR spectra of
the 14-PCSL spin labels show that the preparation
containing the antagonist undergoes chain-melting at
Table 2
Transition temperatures (Tc), half-widths (vTc1=2) and enthalpy
changes (vH) of DPPC bilayers containing di¡erent concentra-
tions of Losartan




DPPC 34.9 41.2 1.2 7.6 1.6 0.3
+Losartan (x = 0.01) 31.8 41.1 0.6 7.4 3.2 0.4
+Losartan (x = 0.05) 25.0 40.6 0.3 7.3 3.9 0.5
+Losartan (x = 0.10) ^ 40.1 ^ 7.0 ^ 0.6
+Losartan (x = 0.20) ^ 39.4 ^ 7.3 ^ 0.7
+Losartan (x = 0.40) ^ 38.4 ^ 7.3 ^ 0.5
+Losartan (x = 0.50) ^ 37.8 ^ 7.3 ^ 0.6
aValues to the left of each column correspond to the pretransi-
tion and those to the right to the main phase transition.
Fig. 4. ESR spectra of 5-, 12- and 14-PCSL spin labels incorpo-
rated either in DMPC bilayers (dotted line) or DMPC bilayers
containing Losartan at mole fraction x = 0.10 (solid line) ob-
tained at the temperatures indicated, over the range 10^35‡C.
The outer hyper¢ne splitting 2Amax for DMPC alone is indi-
cated by dashed lines. Total scan width = 100 G.
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lower temperatures and that the spin probes are
more restricted in motion in both the gel and £uid
phases, relative to the situation at x = 0.10 (vAmax/
(Amax3A0) = 10.1% and 22.6% at 10‡C and 35‡C,
respectively).
At yet higher Losartan concentration x = 0.60 (Fig.
5B), a further shift and widening of the chain-melting
region is induced and, as a result, the spectra of 5-
PCSL spin labels show decreased hyper¢ne splittings
2Amax in the gel phase compared to the correspond-
ing ones of spin labels incorporated into pure DMPC
(vAmax/(Amax3A0) = 3.7% at 10‡C). Although a re-
striction in motion of the spin probes is seen in the
£uid phase, the increase observed in outer hyper¢ne
splittings is smaller than the one evidenced in the
spectra of the preparation containing Losartan at
mole fraction x = 0.40 (vAmax/(Amax3A0) = 5.3% as
opposed to 8.3% at 35‡C). In the case of the
14-PCSL spin labels, the shift and broadening of
the chain-melting region is also seen in the gel phase,
while in the £uid phase, a marked decrease in acyl
chain motion of the spin probes, relative to x = 0.40,
is observed (vAmax/(Amax3A0) = 73.6% as opposed to
22.6% at 35‡C).
Losartan was incorporated also into DPPC bi-
layers at a mole fraction x = 0.10, and the corre-
sponding ESR spectra of 5-, 8-, 12- and 14-PCSL
spin labels are shown in Fig. 6. It is observed that
the 5-PCSL spin label is motionally restricted both in
the gel and in the liquid^crystalline phase due to the
presence of Losartan in the membranes (vAmax/
(Amax3A0) = 3.1% and 3.0% at 30‡C and 43‡C, re-
spectively). Moreover, Losartan shifts the observed
chain-melting transition to between 38 and 40‡C,
while pure DPPC bilayers exhibit this transition be-
tween 41 and 43‡C. A clear reduction of spin^spin
broadening on incorporation of the antagonist in
DPPC bilayers is observed in the gel phase for the
ESR spectra of the 8- and 12-PCSL spin labels, and
to a lesser extent for the 5- and 14-PCSL spin labels.
Additionally, Losartan shifts the chain-melting tran-
sition recorded by the 8-, 12- and 14-PCSL spin la-
bels to lower temperature (between 38 and 40‡C). It
is also observed that the 8- and 12-PCSL spin labels
are restricted in motion by the antagonist in the gel
phase (vAmax/(Amax3A0) = 4.9% and 6.3%, respec-
tively at 20‡C).
ESR spectra of 5- and 14-PCSL spin labels incor-
porated in DPPC membranes containing Losartan at
mole fractions of x = 0.40 and x = 0.60 are shown in
Fig. 7. At drug concentration x = 0.40 (Fig. 7A), a
further shift of the chain-melting transition to
around 34^36‡C is observed in the spectra of the
5-PCSL spin label. Additionally, the 5-PCSL spin
label is motionally restricted in both the gel and £uid
phases, showing greater increases in outer hyper¢ne
splitting 2Amax than at the lower Losartan mole
fraction x = 0.10 (vAmax/(Amax3A0) = 5.3% and
3.9% at 30‡C and 43‡C, respectively). Furthermore,
ESR spectra of the 14-PCSL spin labels show
that the spin probes are more restricted in motion
Fig. 5. ESR spectra of 5- and 14-PCSL spin labels incorporated
either in DMPC bilayers (dotted line) or DMPC bilayers con-
taining Losartan (solid line) at mole fraction x = 0.40 (A) or
x = 0.60 (B) obtained at the temperatures indicated, over the
range 10^35‡C. Total scan width = 100 G.
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both in the gel and in the £uid phase (vAmax/
(Amax3A0) = 31.5% as opposed to 10.7%, and
11.9% as opposed to 10.1% at 20‡C and 43‡C, re-
spectively).
At yet higher concentration of the antagonist
x = 0.60 (Fig. 7B), the e¡ects of the drug are quali-
tatively similar to those described above for mole
fraction x = 0.40. Quantitatively, the e¡ects are cor-
respondingly larger. The 5-PCSL spin label is re-
stricted in motion in both the gel and £uid phases,
showing greater increases in outer hyper¢ne splitting
2Amax than at drug mole fraction x = 0.40 (vAmax/
(Amax3A0) = 6.3% as opposed to 5.3%, and 5.3% as
opposed to 3.9% at 30‡C and 43‡C, respectively). In
the case of the 14-PCSL spin labels, a greater restric-
tion in their motion is observed in the gel phase,
compared to the corresponding one for x = 0.40
(vAmax/(Amax3A0) = 34.8% as opposed to 31.5% at
20‡C). In the liquid^crystalline phase, the restriction
in motion of the spin labels incorporated in the prep-
aration containing the antagonist is smaller com-
pared to the corresponding one that is observed in
the case of mole fraction x = 0.40 (vAmax/
(Amax3A0) = 6.0% as compared with 11.9% at 43‡C).
Fig. 7. ESR spectra of 5- and 14-PCSL spin labels incorporated
either in DPPC bilayers (dotted line) or DPPC bilayers contain-
ing Losartan (solid line) at mole fraction x = 0.40 (A) or
x = 0.60 (B) obtained at the temperatures indicated, over the
range 20^43‡C. Total scan width = 100 G.
Fig. 6. ESR spectra of 5-, 8-, 12- and 14-PCSL spin labels in-
corporated either in DPPC bilayers (dotted line) or DPPC bi-
layers containing Losartan at mole fraction x = 0.10 (solid line)
obtained at the temperatures indicated, over the range 20^43‡C.
Total scan width = 100 G.
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Fig. 8. Temperature dependence of the outer hyper¢ne splitting (2Amax) of 5-PCSL spin label incorporated into DMPC (A) or DPPC
(B) bilayers containing Losartan at di¡erent concentrations. b, Pure phospholipid bilayers; 8, bilayers containing Losartan at mole
fraction x = 0.10; R, bilayers containing Losartan at mole fraction x = 0.40; and F, bilayers containing Losartan at mole fraction
x = 0.60.
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Fig. 8 shows the temperature dependence of the
outer hyper¢ne splittings 2Amax, in the ESR spectra
of 5-PCSL spin label incorporated into DMPC (Fig.
8A) or DPPC (Fig. 8B) bilayers, in the absence and
presence of di¡erent concentrations of Losartan. It is
observed that the incorporation of the antagonist at
increasing mole fractions in DMPC or DPPC bi-
layers causes a progressive shift of the corresponding
chain-melting transitions to lower temperatures. Ad-
ditionally, in DMPC bilayers, the observed transition
is broadened signi¢cantly due to the incorporation of
Losartan at mole fractions v x = 0.40. These results
are in agreement with our DSC data (Figs. 2 and 3).
Furthermore, in Fig. 8 is shown that below and
above the observed chain-melting transition, the val-
ues of 2Amax in the ESR spectra of 5-PCSL spin label
incorporated into DMPC or DPPC bilayers contain-
ing the antagonist are larger than the corresponding
ones in the case of pure phospholipid bilayers. This
indicates a restriction in the spin label motion that is
caused by the presence of Losartan in the mem-
branes. The only exception is the preparation of
DMPC bilayers containing Losartan at mole fraction
x = 0.60, which in the gel phase shows decreased
2Amax value compared to that of DMPC alone. In
this case, the observed chain-melting transition is sig-
ni¢cantly broadened and shifted to low temperatures
and as a result, no restriction in the motion of
5-PCSL spin labels is observed.
4. Discussion
The high incidence of cardiovascular diseases, for
example hypertension and heart failure, has gener-
ated an enormous interest associated with the discov-
ery of non-peptide AT1 receptor antagonists of ANG
II, such as Losartan, an orally active antagonist
which has received FDA approval as a new drug.
The membrane lipid bilayer serves as a structural
and dynamic matrix into which numerous functional
proteins are embedded. A lipophilic drug may pro-
duce some of its e¡ects by perturbing the lipid bi-
layer. This event, which is manifested as a change in
membrane dynamics, may modulate the function of
one or more membrane-associated proteins [30^35].
The elucidation of drug interactions with membranes
and their e¡ects on membrane organization in rela-
tion to their membrane-involving functions is a re-
cent approach to molecular-level mechanisms of ac-
tion (or side e¡ects) of the drugs. Besides its action
on AT1 and AT2 receptors, it is known that ANG II
also interacts with the lipid bilayer of biological
membranes. Our study was aimed to investigate Los-
artan’s interactions with the phospholipid bilayer
component of membranes. The present study is
also essential due to the knowledge that the major
determinants of Losartan binding appear to be resi-
dues located within the transmembrane regions III,
IV, V, VI and VII of the AT1 receptor [36].
Due to the complexity of membrane dynamics and
thermodynamics, a single biophysical method is not
su⁄cient for a detailed analysis of their properties. A
combination of DSC and ESR spectroscopy, two
biophysical techniques that can give complementary
information about the thermotropic and dynamic
properties of biologically active molecules in mem-
branes, was used.
Our DSC results show that Losartan has a very
marked e¡ect on the cooperativity in thermodynamic
properties of DMPC and DPPC bilayers. This is es-
pecially dramatic with DMPC bilayers, for which the
thermotropic transition region is very extensively
broadened and displays a complex endothermic be-
havior characterized by three major calorimetric
peaks (Fig. 2). Both the size of the total calorimetric
enthalpy and the correlation with the temperature
dependence of the spin-label ESR spectra indicate
that this thermotropic behavior is associated with
melting of the lipid chains. The complex endotherms
of DMPC at high Losartan concentration bear a
strong similarity to those found for the anionic lipid
dimyristoylphosphatidylglycerol at low ionic strength
[37]. In the latter case, a broad thermotropic transi-
tion extending from 20 to 28‡C is observed, with two
outer calorimetric peaks and a third broader inter-
mediate calorimetric peak. Most signi¢cantly, this
was accompanied by a large increase in the relative
viscosity of the lipid dispersion in the transition re-
gion, just as is observed here. Recently, it has been
demonstrated that this corresponds to a reversible
transition from a vesicular suspension to an extended
bilayer network in the chain-melting region [38]. Sol-
vent-associated or interfacial interactions favoring a
change in membrane curvature were proposed to ex-
plain this behavior. The strongly enhanced bending
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elasticity arising from lipid-state coexistence in the
chain-melting region is then su⁄cient to induce the
structural transition. It was further demonstrated
that the complex thermotropic behavior involving
three calorimetric peaks is an inevitable thermody-
namic consequence of the structural transition. Al-
most certainly, the same situation holds here with
DMPC and high concentrations of Losartan. Fur-
ther evidence, in addition to the diagnostic calorimet-
ric ¢ngerprint and viscosity anomaly, comes from the
strong lipid chainlength dependence. Only a broad-
ened chain-melting transition, without the character-
istic three-peak structure is found for dipalmitoyl-
phosphatidylglycerol at low ionic strength [38],
exactly as found here for DPPC of the same chain-
length, at high concentrations of Losartan. A more
limited DSC study published previously [39] is qual-
itatively consistent with the present studies. Any
quantitative di¡erences are probably attributable to
the di¡erent experimental conditions used. In partic-
ular, di¡erent water-to-lipid ratios are expected to
a¡ect the degree of partitioning of Losartan into
the membrane.
ESR spectroscopy was performed to study the ef-
fect of Losartan on the chain motion and packing in
bilayer membranes by using di¡erent positional iso-
mers of phosphatidylcholine (n-PCSL) spin probes
incorporated in DMPC or DPPC bilayers. The
ESR spectra obtained showed that Losartan shifted
the chain-melting phase transition to lower temper-
atures and broadened the region of phase coexis-
tence, in agreement with DSC data (Figs. 2 and 3).
A decrease in chain mobility of phosphatidylcho-
line bilayers is induced by the incorporation of an-
tagonist, both in the gel and £uid phases of the mem-
brane (Figs. 4^7). In the £uid phase, this change was
registered more sensitively by the spin label on the 5-
position than by spin labels positioned further down
the chain. This could indicate that Losartan is lo-
cated closer to the interfacial region than to the hy-
drophobic core of the phosphatidylcholine bilayer.
Interestingly, Losartan improves the solubility of
the lipid probes, and possibly of other components,
in the gel phase of phosphatidylcholine bilayers. This
is seen from the reduction in spin^spin interactions
between the 12-PCSL probes and suggests that incor-
poration of Losartan relaxes the tight chain packing
in the gel phase, even though the segmental mobility
is reduced. Increasing the concentration of Losartan
to x = 0.40, progressively decreases the chain mobility
in the DMPC and DPPC gel and £uid phases (Figs.
5 and 7). At a very high mole fraction (x = 0.60) in
DMPC bilayers, the e¡ects of antagonist di¡er qual-
itatively from those at lower molar fractions. The
chain segmental mobility is then increased in the
gel phase of DMPC, and the decrease in chain mo-
bility registered by 5-PCSL in the £uid phase is
smaller, whereas that registered by 14-PCSL is fur-
ther increased. This indicates a di¡erent mode of
interaction with Losartan, possibly arising from a
location deeper within the bilayer at high mole frac-
tions of antagonist.
Our results, as far as we know, are one of the ¢rst
studies of the interactions of non-peptide ANG II
AT1 receptor antagonists with phospholipid mem-
branes. Using DSC, we have shown that Losartan
is able to intercalate in phosphatidylcholine bilayers.
ESR spectroscopy showed that one possible mode of
insertion is location of Losartan’s polar hydroxyl
group near the carbonyl groups of the phospholipids,
with which it could form hydrogen bonds. Then the
butyl chain of the antagonist could be extended in
the hydrophobic region of the bilayer and the tetra-
zole group located near the phosphate of the phos-
pholipid headgroups. This hypothesis is supported by
the ¢nding that the greater e¡ect of the antagonist on
acyl chain mobility of the spin probes was observed
in the spectra of 5-PCSLs. A similar membrane lo-
cation was also proposed for classical cannabinoid
molecules possessing a phenolic hydroxyl group
[18,21,40,41]. At high drug concentrations, it seems
that Losartan inserts deeper in the bilayers, a¡ecting
more strongly the mobility of 14-PCSL spin probes
for DMPC and DPPC membranes while the mobility
of 5-PCSL is less a¡ected. This may be caused by
self-association of Losartan with intermolecular
bonding of its polar hydroxyl groups that results in
a more hydrophobic behavior of the antagonist. A
similar e¡ect was observed with cyclosporin incorpo-
rated in dielaidoylphosphatidylethanolamine mem-
branes [42].
In conclusion, our study has shown that Losartan
interacts with phospholipid membranes by a¡ecting
both their thermotropic behavior and molecular mo-
bility. Particularly striking is the e¡ect that high con-
centration of Losartan has on the chain-melting be-
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havior of DMPC and the associated changes in ve-
sicular structure that are induced in this region.
These results must be taken into account in the phar-
macological application of the antagonist and open
up the possibility that Losartan, besides its antago-
nist action on the receptor level, could exert some of
its e¡ects through its interaction with the lipids of the
membrane bilayer.
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